JP2009531068A - Ｒａｓ変異並びにこれに関連する組成物及び方法 - Google Patents

Ｒａｓ変異並びにこれに関連する組成物及び方法 Download PDF

Info

Publication number
JP2009531068A
JP2009531068A JP2009503126A JP2009503126A JP2009531068A JP 2009531068 A JP2009531068 A JP 2009531068A JP 2009503126 A JP2009503126 A JP 2009503126A JP 2009503126 A JP2009503126 A JP 2009503126A JP 2009531068 A JP2009531068 A JP 2009531068A
Authority
JP
Japan
Prior art keywords
ras
protein
amino acid
nucleic acid
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503126A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009531068A5 (https=
Inventor
グオ，ジミン
ル，インニェン
ベルグラウ，ドナルド
フランツソッフ，アレックス
Original Assignee
グローブイミューン，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グローブイミューン，インコーポレイテッド filed Critical グローブイミューン，インコーポレイテッド
Publication of JP2009531068A publication Critical patent/JP2009531068A/ja
Publication of JP2009531068A5 publication Critical patent/JP2009531068A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
JP2009503126A 2006-03-27 2007-03-09 Ｒａｓ変異並びにこれに関連する組成物及び方法 Pending JP2009531068A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78656806P 2006-03-27 2006-03-27
PCT/US2007/063711 WO2007133835A2 (en) 2006-03-27 2007-03-09 Ras mutation and compositions and mehods related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014198353A Division JP2015043773A (ja) 2006-03-27 2014-09-29 Ｒａｓ変異並びにこれに関連する組成物及び方法

Publications (2)

Publication Number Publication Date
JP2009531068A true JP2009531068A (ja) 2009-09-03
JP2009531068A5 JP2009531068A5 (https=) 2010-04-22

Family

ID=38694572

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009503126A Pending JP2009531068A (ja) 2006-03-27 2007-03-09 Ｒａｓ変異並びにこれに関連する組成物及び方法
JP2014198353A Pending JP2015043773A (ja) 2006-03-27 2014-09-29 Ｒａｓ変異並びにこれに関連する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014198353A Pending JP2015043773A (ja) 2006-03-27 2014-09-29 Ｒａｓ変異並びにこれに関連する組成物及び方法

Country Status (12)

Country Link
US (3) US7745128B2 (https=)
EP (1) EP2004666B1 (https=)
JP (2) JP2009531068A (https=)
KR (1) KR20090008290A (https=)
CN (1) CN101448848B (https=)
AU (1) AU2007249639B2 (https=)
BR (1) BRPI0709340A2 (https=)
CA (1) CA2647102A1 (https=)
MX (1) MX2008012392A (https=)
SG (1) SG170763A1 (https=)
TW (1) TW200806789A (https=)
WO (1) WO2007133835A2 (https=)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509595A (ja) * 2011-03-17 2014-04-21 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
JP2014514333A (ja) * 2011-04-29 2014-06-19 セレクタ バイオサイエンシーズ インコーポレーテッド アレルギー治療用寛容原性合成ナノキャリア
JP2015528110A (ja) * 2012-06-26 2015-09-24 バイオデシックス・インコーポレイテッドＢｉｏｄｅｓｉｘ Ｉｎｃ 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法
JP2015527874A (ja) * 2012-05-31 2015-09-24 バイエル ファーマ アクチエンゲゼルシャフト 肝細胞癌（ｈｃｃ）患者の治療の有効な応答を決定するためのバイオマーカー
JP2018518177A (ja) * 2015-06-16 2018-07-12 タルゴバックス エーエスエー Ｒａｓタンパク質の突然変異フラグメント
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
US10335395B2 (en) 2013-05-03 2019-07-02 Selecta Biosciences, Inc. Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
JP2020514321A (ja) * 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR101455222B1 (ko) * 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN103424541B (zh) 2006-05-18 2018-01-30 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
WO2008097863A2 (en) * 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) * 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
EP3711755A1 (en) 2007-06-29 2020-09-23 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Method of fixing and expressing physiologically active substance
KR100957555B1 (ko) 2007-12-28 2010-05-11 덕성여자대학교 산학협력단 Ｒａｓ 융합 단백질
WO2009099991A2 (en) * 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
WO2010028288A2 (en) 2008-09-05 2010-03-11 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
US20100075326A1 (en) * 2008-09-12 2010-03-25 Cornell University Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
KR101153845B1 (ko) 2008-11-10 2012-07-09 단국대학교 산학협력단 Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임
WO2010056337A2 (en) 2008-11-12 2010-05-20 Caris Mpi, Inc. Methods and systems of using exosomes for determining phenotypes
CN103555722B (zh) 2009-04-03 2016-08-31 戴瑟纳制药公司 利用不对称双链rna特异性抑制kras的方法和组合物
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
CA2786696C (en) * 2010-01-12 2021-05-25 Jill Detmer Oligonucleotides and methods for detecting pik3ca mutations
EP2542696B1 (en) 2010-03-01 2016-09-28 Caris Life Sciences Switzerland Holdings GmbH Biomarkers for theranostics
JP2013526852A (ja) 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
MX342055B (es) * 2010-04-12 2016-09-12 Response Genetics Inc Iniciadores y sondas de kras.
EP2619329B1 (en) 2010-09-24 2019-05-22 The Board of Trustees of The Leland Stanford Junior University Direct capture, amplification and sequencing of target dna using immobilized primers
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
US9556473B2 (en) 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
CN103649331A (zh) 2011-02-15 2014-03-19 莱卡生物系统纽卡斯尔有限责任公司 用于mrna的定位的原位检测的方法
CN102796811B (zh) * 2011-05-26 2013-12-18 上海赛安生物医药科技有限公司 检测kras突变的试剂及方法
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
CN104126017A (zh) * 2011-11-11 2014-10-29 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
US9260714B2 (en) * 2011-12-02 2016-02-16 Roche Molecular Systems, Inc. Suppression of non-specific amplification with high-homology oligonucleotides
KR101153844B1 (ko) 2012-04-17 2012-06-20 단국대학교 산학협력단 Ｋｒａｓ Ｇ１２Ｖ ＲＮＡ를 특이적으로 인지할 수 있는 트랜스-스플라이싱 그룹 Ｉ 리보자임
EP2929351B1 (en) * 2012-12-10 2019-10-09 The University of Queensland Cell-free biofragment compositions and related systems, devices, and methods
AU2014265873B2 (en) 2013-03-19 2019-01-17 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
WO2015059677A1 (en) 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
JP6781403B2 (ja) * 2013-12-09 2020-11-04 タルゴバックス エーエスエー ペプチド混合物
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
US11331312B2 (en) 2014-04-25 2022-05-17 Memorial Sloan-Kettering Cancer Center Treatment of H-Ras-driven tumors
KR101602876B1 (ko) * 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
US10829752B2 (en) * 2014-08-01 2020-11-10 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
US12415995B2 (en) 2014-08-01 2025-09-16 Northwestern University Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders
EP3180463B1 (en) * 2014-08-15 2023-08-30 Medimmune, LLC Detecting residual host cell proteins in recombinant protein preparations
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
US10612032B2 (en) 2016-03-24 2020-04-07 The Board Of Trustees Of The Leland Stanford Junior University Inducible production-phase promoters for coordinated heterologous expression in yeast
MX2018014554A (es) 2016-05-27 2019-09-09 Orum Therapeutics Inc Anticuerpo penetrante de citosol y uso del mismo.
CN110268057B (zh) 2016-11-16 2024-03-29 斯坦福大学托管董事会 用于鉴定和表达基因簇的系统和方法
WO2018145020A1 (en) * 2017-02-03 2018-08-09 The Medical College Of Wisconsin, Inc. Kras peptide vaccine compositions and method of use
WO2018146253A1 (en) 2017-02-10 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
SG11201911430PA (en) * 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
CN108440647A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440646A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108484730A (zh) * 2018-04-02 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108440648A (zh) * 2018-04-02 2018-08-24 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108250269A (zh) * 2018-04-02 2018-07-06 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN108484731A (zh) * 2018-04-02 2018-09-04 天津亨佳生物科技发展有限公司 一种治疗肿瘤的抗原肽链组及其在药物中的应用
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
US10787487B2 (en) 2018-06-21 2020-09-29 Orum Therapeutics Inc. Cell/tissue-specific cell-penetrating antibodies
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
AU2021254753A1 (en) 2020-04-14 2022-08-25 Nantcell, Inc. Yeast lysate COVID-19 vaccine
CN116438308A (zh) * 2020-08-06 2023-07-14 磨石生物公司 多表位疫苗盒

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500650A (ja) * 1993-07-26 1997-01-21 ケイ．オー．テクノロジー インコーポレイテッド ガン治療薬の主薬としての遺伝子の異なる対立遺伝子の阻害剤
WO2001027260A1 (fr) * 1999-10-15 2001-04-19 Wakenyaku Co., Ltd. Molecule matricielle presentant un vaste champ d'applications et dispositif hautement efficace de synthese acellulaire de proteines utilisant cette molecule
JP2002511265A (ja) * 1998-04-15 2002-04-16 ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション 新規のヒト転写因子に基づく緑内障治療薬および診断薬
JP2003518951A (ja) * 2000-01-05 2003-06-17 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 多型核酸配列の同時増幅およびリアルタイム検出のための方法
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
JP2005512596A (ja) * 2001-12-24 2005-05-12 キャンサー・リサーチ・テクノロジー・リミテッド 哺乳類の細胞におけるｓｉＲＮＡＳの安定発現のための系
JP2006509521A (ja) * 2002-12-13 2006-03-23 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミントランスポーター遺伝子多型

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2377188A (en) * 1941-08-07 1945-05-29 Schering Corp Stabilized filter preparations
US2376884A (en) * 1941-08-07 1945-05-29 Schering Corp Hydroquinone composition
US3856934A (en) * 1970-06-24 1974-12-24 A Kligman Skin depigmentation
US3755560A (en) * 1971-06-30 1973-08-28 Dow Chemical Co Nongreasy cosmetic lotions
US4136166A (en) * 1977-04-18 1979-01-23 Helena Rubinstein, Inc. Skin lightening composition
US4229427A (en) * 1978-06-28 1980-10-21 The Procter & Gamble Company Radioactive scanning agents with hydroquinone stabilizer
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57145803A (en) * 1981-03-05 1982-09-09 Sunstar Inc External decoloring agent for skin
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
US4775622A (en) * 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4466955A (en) * 1982-06-09 1984-08-21 Germaine Monteil Cosmetiques Corporation Skin bleaching stick containing hydroquinone
US4725550A (en) 1984-01-19 1988-02-16 Research Foundation Of State University Of New York Novel mutation of the c-K-ras oncogene activated in a human lung carcinoma
US5591582A (en) * 1985-07-23 1997-01-07 The Board Of Rijks Universiteit Leiden Methods for detecting activated RAS oncogenes
US4871838A (en) 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
US4792443A (en) * 1985-12-20 1988-12-20 Warner-Lambert Company Skin bleaching preparations
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
JPH0474515A (ja) * 1990-07-13 1992-03-09 Toray Ind Inc 酸素吸収体
GB9103974D0 (en) * 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5523077A (en) * 1992-02-06 1996-06-04 Yale University Composition and method for whitening skin
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
GB9422814D0 (en) * 1994-11-11 1995-01-04 Medinnova Sf Chemical method
US5858378A (en) * 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
US6497860B1 (en) * 1996-11-04 2002-12-24 Children's Hospital Medical Center Skin lightening compositions
US6060297A (en) * 1997-04-17 2000-05-09 Incyte Pharmaceuticals, Inc. Rho protein
US5945306A (en) * 1997-12-16 1999-08-31 Incyte Pharmaceuticals, Inc. Ras protein
US6017710A (en) * 1998-05-13 2000-01-25 Axys Pharmaceuticals, Inc. RAQ genes and their uses
NO309798B1 (no) 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
AU1951001A (en) * 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7189759B2 (en) * 2001-05-23 2007-03-13 Medicis Pharmaceutical Corporation Compositions for the treatment of pigmentation disorders and methods for their manufacture
US6699464B1 (en) * 2001-07-30 2004-03-02 Stiefel Laboratories, Inc. Compositions for treatment of hyperpigmentation and methods for making and using such compositions
US20040185016A1 (en) * 2002-07-30 2004-09-23 Popp Karl F Compositions for treatment of hyperpigmentation and methods for making and using such compositions
KR101455222B1 (ko) * 2002-12-16 2014-10-31 글로브이뮨 면역 요법으로서의 효모계 백신
SG163572A1 (en) 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune, Inc. mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09500650A (ja) * 1993-07-26 1997-01-21 ケイ．オー．テクノロジー インコーポレイテッド ガン治療薬の主薬としての遺伝子の異なる対立遺伝子の阻害剤
JP2002511265A (ja) * 1998-04-15 2002-04-16 ザ ユニヴァーシティー オブ アイオワ リサーチ ファンデーション 新規のヒト転写因子に基づく緑内障治療薬および診断薬
WO2001027260A1 (fr) * 1999-10-15 2001-04-19 Wakenyaku Co., Ltd. Molecule matricielle presentant un vaste champ d'applications et dispositif hautement efficace de synthese acellulaire de proteines utilisant cette molecule
JP2003518951A (ja) * 2000-01-05 2003-06-17 ジョンソン・アンド・ジョンソン・リサーチ・ピー・ティー・ワイ・リミテッド 多型核酸配列の同時増幅およびリアルタイム検出のための方法
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
JP2005512596A (ja) * 2001-12-24 2005-05-12 キャンサー・リサーチ・テクノロジー・リミテッド 哺乳類の細胞におけるｓｉＲＮＡＳの安定発現のための系
JP2006509521A (ja) * 2002-12-13 2006-03-23 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミントランスポーター遺伝子多型

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
JPN6012026615; ＨＡＮ，　Ｚ．: '"Ｓｃｈｉｓｔｏｓｏｍａ　ｊａｐｏｎｉｃｕｍ　ＳＪＣＨＧＣ０９４０８　ｐｒｏｔｅｉｎ　ｍＲＮＡ，　ｃｏｍｐｌｅｔｅ　ｃｄｓ"' ＧｅｎＢａｎｋ：ＡＹ８１３０８２ , 20050923 *
JPN6012026617; ＦＲＥＩＴＡＳ，　Ｒ．Ｎ．　ｅｔ　ａｌ．: Ｍｕｔａｔｉｏｎ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．４９９, 2002, ｐｐ．１８９-１９６ *
JPN6012026619; ＴＡＯ，　Ｌ．-Ｆ．　ｅｔ　ａｌ．: Ａｎｔｉｓｅｎｓｅ　Ｒｅｓ．　Ｄｅｖ． Ｖｏｌ．５, 1995, ｐｐ．１２３-１２９ *
JPN6012026620; ＬＩＵ，　Ｆ．　ｅｔ　ａｌ．: ＰＬＯＳ　Ｐａｔｈｏｇｅｎｓ Ｖｏｌ．２，　Ｎｏ．４, 200604, ｅ２９ *
JPN6012026622; ＫＲＥＩＭＥＲ-ＥＲＬＡＣＨＥＲ，　Ｈ．　ｅｔ　ａｌ．: Ｐｈｏｔｏｃｈｅｍ．　Ｐｈｏｔｏｂｉｏｌ． Ｖｏｌ．７４，　Ｎｏ．２, 2001, ｐｐ．３２３-３３０ *
JPN6012026624; ＥＳＴＥＬＬＥＲ，　Ｍ．　ｅｔ　ａｌ．: Ｅｕｒ．　Ｊ．　Ｃａｎｃｅｒ Ｖｏｌ．３３，　Ｎｏ．１０, 1997, ｐｐ．１５７２-１５７７ *
JPN6012026626; ＭＡＮＡＭ，　Ｓ．　ａｎｄ　ＮＩＣＨＯＬＳ　Ｗ．Ｗ．: Ａｎａｌ．　Ｂｉｏｃｈｅｍ． Ｖｏｌ．１９９, 1991, ｐｐ．１０６-１１１ *
JPN6013038724; ＧＡＭＢＯＡ-ＤＯＭＩＮＧＵＥＺ，　Ａ．　ｅｔ　ａｌ．: Ｈｕｍ．　Ｐａｔｈｏｌ． Ｖｏｌ．３６, 2005, ｐｐ．２９-３５ *
JPN6013038725; ＲＵＴＡ，　Ｍ．　ｅｔ　ａｌ．: Ｍｏｌ．　Ｃｅｌｌ．　Ｂｉｏｌ． Ｖｏｌ．６，　Ｎｏ．５, 1986, ｐｐ．１７０６-１７１０ *
JPN6013038726; ＢＥＣＫＥＲ，　Ｋ．-Ｆ．　ｅｔ　ａｌ．: Ａｍ．　Ｊ．　Ｐａｔｈｏｌ． Ｖｏｌ．１５５，　Ｎｏ．６, 1999, ｐｐ．１８０３-１８０９ *
JPN6013038727; ＢＥＣＫＥＲ，　Ｋ．-Ｆ．　ｅｔ　ａｌ．: Ｊ．　Ｐａｔｈｏｌ． Ｖｏｌ．１９７, 2002, ｐｐ．５６７-５７４ *
JPN6014021516; 新村出　編: 広辞苑 , 1998, 第１６４８頁，　第２８２７頁, 第５版 *
JPN6014021518; ＭＯＳＴＥＬＬＥＲ，　Ｒ．Ｄ．　ｅｔ　ａｌ．: Ｍｏｌ．　Ｃｅｌｌ．　Ｂｉｏｌ． Ｖｏｌ．１４，　Ｎｏ．２, 1994, ｐｐ．１１０４-１１１２ *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509595A (ja) * 2011-03-17 2014-04-21 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
US11235057B2 (en) 2011-04-29 2022-02-01 Selecta Biosciences, Inc. Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US10004802B2 (en) 2011-04-29 2018-06-26 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
JP2014514333A (ja) * 2011-04-29 2014-06-19 セレクタ バイオサイエンシーズ インコーポレーテッド アレルギー治療用寛容原性合成ナノキャリア
JP2017122110A (ja) * 2011-04-29 2017-07-13 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． アレルギー治療用寛容原性合成ナノキャリア
JP2017122112A (ja) * 2011-04-29 2017-07-13 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 抗体反応を低下させる寛容原性合成ナノキャリア
US9987354B2 (en) 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US9993548B2 (en) 2011-04-29 2018-06-12 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for inducing regulatory B cells
US10441651B2 (en) 2011-04-29 2019-10-15 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
US11779641B2 (en) 2011-04-29 2023-10-10 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US10039822B2 (en) 2011-04-29 2018-08-07 Selecta Biosciences, Inc. Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11717569B2 (en) 2011-04-29 2023-08-08 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
US10420835B2 (en) 2011-04-29 2019-09-24 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
JP2015527874A (ja) * 2012-05-31 2015-09-24 バイエル ファーマ アクチエンゲゼルシャフト 肝細胞癌（ｈｃｃ）患者の治療の有効な応答を決定するためのバイオマーカー
JP2015528110A (ja) * 2012-06-26 2015-09-24 バイオデシックス・インコーポレイテッドＢｉｏｄｅｓｉｘ Ｉｎｃ 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法
US10434088B2 (en) 2013-05-03 2019-10-08 Selecta Biosciences, Inc. Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
US10357482B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US12508249B2 (en) 2013-05-03 2025-12-30 Cartesian Therapeutics Inc. Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis
US10335395B2 (en) 2013-05-03 2019-07-02 Selecta Biosciences, Inc. Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
US12472167B2 (en) 2013-05-03 2025-11-18 Cartesian Therapeutics, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity
US10668053B2 (en) 2013-05-03 2020-06-02 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
US10357483B2 (en) 2013-05-03 2019-07-23 Selecta Biosciences, Inc. Methods comprising dosing combinations for reducing undesired humoral immune responses
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
US10071114B2 (en) 2014-09-07 2018-09-11 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
JP2018518177A (ja) * 2015-06-16 2018-07-12 タルゴバックス エーエスエー Ｒａｓタンパク質の突然変異フラグメント
JP2020514321A (ja) * 2017-02-01 2020-05-21 モデルナティーエックス， インコーポレイテッド 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物
US12194078B2 (en) 2017-03-11 2025-01-14 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Also Published As

Publication number Publication date
WO2007133835A8 (en) 2010-11-11
CN101448848B (zh) 2013-12-04
CN101448848A (zh) 2009-06-03
US8470313B2 (en) 2013-06-25
AU2007249639A1 (en) 2007-11-22
US7745128B2 (en) 2010-06-29
WO2007133835A2 (en) 2007-11-22
EP2004666A2 (en) 2008-12-24
MX2008012392A (es) 2008-12-17
EP2004666A4 (en) 2009-11-18
CA2647102A1 (en) 2007-11-22
US20100215678A1 (en) 2010-08-26
TW200806789A (en) 2008-02-01
WO2007133835A3 (en) 2008-11-13
US20130344097A1 (en) 2013-12-26
AU2007249639B2 (en) 2012-05-31
EP2004666B1 (en) 2014-09-03
SG170763A1 (en) 2011-05-30
JP2015043773A (ja) 2015-03-12
US20070224208A1 (en) 2007-09-27
KR20090008290A (ko) 2009-01-21
BRPI0709340A2 (pt) 2013-04-16

Similar Documents

Publication Publication Date Title
US7745128B2 (en) Ras mutation and compositions and methods related thereto
JP5809067B2 (ja) 癌の診断および治療のための方法および組成物
JP5808254B2 (ja) 癌の診断および治療のための方法および組成物
KR102409372B1 (ko) 효모 면역 요법 및 타입 i 인터페론 감도
US20190111120A1 (en) Novel cancer antigen eef2
TW201716574A (zh) 經修飾之酵母－短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
WO2015123532A1 (en) Ras g12r immunotherapy for ras mutation-positive cancers
TWI674108B (zh) 索脊瘤之以酵母菌爲基礎之免疫療法
HK1232453B (en) Novel cancer antigen eef2
HK1192150B (en) Novel cancer antigen eef2
HK1189514B (en) Eef2-derived peptides for the treatment or prevention of cancer
HK1166999B (en) Novel cancer antigen eef2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100305

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100305

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110114

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110225

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110613

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110628

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140929